Galera Therapeutics (GRTX) Competitors $0.03 +0.00 (+12.73%) (As of 12/20/2024 03:47 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends GRTX vs. ONVO, CNSP, GTBP, SYRS, HOTH, PPBT, IMCC, ELAB, CANF, and BMRAShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Organovo (ONVO), CNS Pharmaceuticals (CNSP), GT Biopharma (GTBP), Syros Pharmaceuticals (SYRS), Hoth Therapeutics (HOTH), Purple Biotech (PPBT), IM Cannabis (IMCC), Elevai Labs (ELAB), Can-Fite BioPharma (CANF), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Organovo CNS Pharmaceuticals GT Biopharma Syros Pharmaceuticals Hoth Therapeutics Purple Biotech IM Cannabis Elevai Labs Can-Fite BioPharma Biomerica Organovo (NASDAQ:ONVO) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability. Which has preferable earnings & valuation, ONVO or GRTX? Organovo has higher revenue and earnings than Galera Therapeutics. Organovo is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganovo$103K53.71-$14.67M-$1.06-0.34Galera TherapeuticsN/AN/A-$59.08M-$0.35-0.09 Do insiders & institutionals have more ownership in ONVO or GRTX? 8.2% of Organovo shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 3.7% of Organovo shares are held by insiders. Comparatively, 6.9% of Galera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is ONVO or GRTX more profitable? Galera Therapeutics has a net margin of 0.00% compared to Organovo's net margin of -12,176.70%. Galera Therapeutics' return on equity of 0.00% beat Organovo's return on equity.Company Net Margins Return on Equity Return on Assets Organovo-12,176.70% -249.28% -159.50% Galera Therapeutics N/A N/A -116.47% Which has more volatility & risk, ONVO or GRTX? Organovo has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Does the MarketBeat Community prefer ONVO or GRTX? Organovo received 146 more outperform votes than Galera Therapeutics when rated by MarketBeat users. However, 54.35% of users gave Galera Therapeutics an outperform vote while only 47.34% of users gave Organovo an outperform vote. CompanyUnderperformOutperformOrganovoOutperform Votes19647.34% Underperform Votes21852.66% Galera TherapeuticsOutperform Votes5054.35% Underperform Votes4245.65% Does the media prefer ONVO or GRTX? In the previous week, Organovo's average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score. Company Overall Sentiment Organovo Neutral Galera Therapeutics Neutral SummaryGalera Therapeutics beats Organovo on 9 of the 12 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.0510.5989.9717.18Price / SalesN/A196.061,116.26117.06Price / CashN/A57.1643.1037.85Price / Book-0.015.094.784.78Net Income-$59.08M$151.83M$120.31M$225.60M7 Day PerformanceN/A-2.14%-1.92%-1.23%1 Month PerformanceN/A-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.03+12.7%N/A-76.3%$1.50MN/A-0.0530Gap DownONVOOrganovoN/A$0.39-3.6%N/A-67.6%$5.99M$110,000.000.0020Analyst ForecastCNSPCNS Pharmaceuticals1.224 of 5 stars$0.10-1.2%$0.50+391.6%-99.8%$5.85MN/A0.005Gap DownGTBPGT Biopharma3.6544 of 5 stars$2.59-5.8%$11.00+324.7%-78.3%$5.79MN/A0.008Gap UpSYRSSyros Pharmaceuticals4.2571 of 5 stars$0.21+3.4%$3.33+1,455.5%-96.5%$5.75M$9.94M-0.07120Gap UpHOTHHoth Therapeutics2.0095 of 5 stars$0.82+1.2%$3.50+326.8%-30.8%$5.66MN/A-0.614Gap UpPPBTPurple Biotech1.6602 of 5 stars$4.05+5.7%$33.00+714.8%N/A$5.39MN/A-0.4720IMCCIM Cannabis0.0474 of 5 stars$2.40-2.8%N/A+3.4%$5.36M$51.39M-0.72340Gap DownELABElevai Labs0.3441 of 5 stars$2.06-10.0%N/A-99.3%$5.33M$2.45M-0.0318News CoverageGap DownCANFCan-Fite BioPharma1.7922 of 5 stars$1.50-5.1%$14.00+833.3%-30.7%$5.31M$667,000.00-0.888BMRABiomerica0.1417 of 5 stars$0.31+0.1%N/A-76.8%$5.28M$5.51M-0.8260Gap Down Related Companies and Tools Related Companies ONVO Competitors CNSP Competitors GTBP Competitors SYRS Competitors HOTH Competitors PPBT Competitors IMCC Competitors ELAB Competitors CANF Competitors BMRA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRTX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
